Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence...
Brief Summary
Official Title: “Treatment Efficacy for Drug Abuse and AIDS Prevention”
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.
- Study Type: Interventional
- Study Design: Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Buprenorphine
Criteria for Participation in this Clinical Trial
- Please contact site for information.
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 26 Years
Maximum Age for this Clinical Trial: 41 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: National Institute on Drug Abuse (NIDA) NIH
Overall Clinical Trial Officials and Contacts
Jack Mendelson, M.D. Principal Investigator Mclean Hospital
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00000211
Study ID Number: NIDA-06116-2
ClinicalTrials.gov Identifier: NCT00000211
Health Authority: United States: Federal Government
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00000211
